About Royalty Pharma PLC
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.royaltypharma.com/
Frequently Asked Questions
What is the 52-week range for RPRX?
The 52-week high is $64.38 and the 52-week low is $35.23.
What is the P/E ratio for RPRX?
The Price to Earnings (P/E) ratio is 40.36.
What is the dividend yield for RPRX?
The indicated annual dividend yield is 2.96%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 12.25%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 32.14%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.44.
Analyst Recommendation Trends
Wall Street analyst consensus for RPRX over the last few months:
Latest RPRX News
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma (NASDAQ:RPRX) executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage. Speaking during a firesid
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Bank of America Global Healthcare Conference 2026 September 23, 2026 6:45 AM EDTCompany ParticipantsTerrance Coyne - Executive VP...
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
Royalty Pharma has delivered a strong share price run in recent years, which naturally puts fresh attention on what investors are paying for its earnings today. With the stock now around US$58.52, the key issue is how that outcome lines up with the underlying profit engine of its royalty portfolio. Over the last 3 years, Royalty Pharma has returned about 136.3%, which increases the stakes on whether its current earnings base can carry that kind of share price progress. The recent US$7.5...
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
Royalty Pharma (RPRX) is set to present at the Bank of America Global Healthcare Conference in London on September 23, 2026. The appearance will put its biopharmaceutical royalty model back in front of institutional investors. Recent trading hints at cooling momentum in Royalty Pharma’s share price in the very short term, with a 30-day share price return down 4.6%, even as the 90-day share price return of 7.8% and 1-year total shareholder return of 64.6% point to a much stronger longer-run...
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies. The donation marks a new phase for TAP, with Royalty Pharma s
Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 2:35 PM EDTCompany ParticipantsPablo Legorreta -...
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDTBofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market capitalization of
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1). The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Read Also: A Wall St
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, an
Dividend Champion, Contender, And Challenger Highlights: Week September 6
Explore this weekâs dividend updates for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend and pay dates.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Hite Christopher | -3,927 | $58.9261 | $231,403 |
| 2026-09-22 | Hite Christopher | -96,073 | $58.5148 | $5,621,692 |
| 2026-08-19 | Hite Christopher | -16,800 | - | - |
| 2026-08-18 | Hite Christopher | -100,000 | $59.9725 | $5,997,250 |
| 2026-08-13 | Coyne Terrance P. | -1,772 | $59.1415 | $104,799 |
| 2026-08-13 | Coyne Terrance P. | -9,230 | $58.5864 | $540,752 |
| 2026-08-07 | Urist Marshall | -3,000 | - | - |
| 2026-08-07 | Coyne Terrance P. | -18,500 | - | - |
| 2026-08-07 | Legorreta Pablo G. | -30,000 | - | - |
| 2026-08-05 | Urist Marshall | +8,252 | - | - |
| 2026-08-05 | Coyne Terrance P. | +11,002 | - | - |
| 2026-08-05 | Hite Christopher | +11,002 | - | - |
| 2026-08-05 | Legorreta Pablo G. | +65,216 | - | - |
| 2026-07-01 | Urist Marshall | -9,099 | $55.8802 | $508,454 |
| 2026-06-30 | Hite Christopher | -600 | $57.09 | $34,254 |
| 2026-06-30 | Hite Christopher | -29,400 | $56.4423 | $1,659,404 |
| 2026-06-30 | Hite Christopher | -2,554 | $57.1031 | $145,841 |
| 2026-06-30 | Hite Christopher | -97,446 | $56.5028 | $5,505,972 |
| 2026-06-24 | Urist Marshall | -9,098 | $55.1843 | $502,067 |
| 2026-06-23 | Hite Christopher | -117,592 | $54.4746 | $6,405,777 |
| 2026-06-23 | Hite Christopher | -32,408 | $54.107 | $1,753,500 |
| 2026-06-05 | Engelbert Catherine M. | +4,545 | - | - |
| 2026-06-05 | Ho Carole | +4,545 | - | - |
| 2026-06-05 | Coric Vlad | +4,545 | - | - |
| 2026-06-05 | Bassler Bonnie L | +4,545 | - | - |
| 2026-06-05 | Norden Gregory | +4,545 | - | - |
| 2026-06-05 | HODGSON DAVID C | +4,545 | - | - |
| 2026-06-05 | LOVE TED W | +4,545 | - | - |
| 2026-06-05 | WEATHERMAN ELIZABETH H | +4,545 | - | - |
| 2026-05-26 | Coyne Terrance P. | -64,399 | $53.9778 | $3,476,116 |
| 2026-05-20 | Urist Marshall | -13,684 | $52.7505 | $721,838 |
| 2026-05-14 | Urist Marshall | -13,684 | $53.0647 | $726,137 |
| 2026-05-14 | Norden Gregory | -3,045 | $53 | $161,385 |
| 2026-05-06 | Coyne Terrance P. | +24,263 | - | - |
| 2026-05-06 | Urist Marshall | +18,197 | - | - |
| 2026-05-06 | Hite Christopher | +24,263 | - | - |
| 2026-05-06 | Legorreta Pablo G. | +143,821 | - | - |
| 2026-04-28 | Coyne Terrance P. | -1,875 | $49.7784 | $93,335 |
| 2026-04-28 | Coyne Terrance P. | -32,916 | $49.7784 | $1,638,506 |
| 2026-04-01 | Coyne Terrance P. | -32,916 | $48.3318 | $1,590,890 |
| 2026-04-01 | Coyne Terrance P. | -1,875 | $48.3318 | $90,622 |
| 2026-03-31 | Bassler Bonnie L | +815 | $45.977 | $37,471 |
| 2026-03-23 | Coyne Terrance P. | -1,875 | $45.5287 | $85,366 |
| 2026-03-23 | Coyne Terrance P. | -32,916 | $45.5287 | $1,498,623 |
| 2026-03-02 | Coyne Terrance P. | -583 | $47.0143 | $27,409 |
| 2026-03-02 | Coyne Terrance P. | -1,292 | $46.6747 | $60,304 |
| 2026-03-02 | Coyne Terrance P. | -10,429 | $47.0145 | $490,314 |
| 2026-03-02 | Coyne Terrance P. | -22,487 | $46.6717 | $1,049,507 |
| 2026-02-23 | Coyne Terrance P. | -1,875 | $45.3165 | $84,968 |
| 2026-02-23 | Coyne Terrance P. | -32,916 | $45.3165 | $1,491,638 |
| 2026-02-11 | Urist Marshall | +19,970 | - | - |
| 2026-02-11 | Coyne Terrance P. | +26,626 | - | - |
| 2026-02-11 | Hite Christopher | +26,626 | - | - |
| 2026-02-11 | Legorreta Pablo G. | +157,828 | - | - |
| 2026-02-04 | Coyne Terrance P. | -1,087 | $43.2928 | $47,059 |
| 2026-02-04 | Coyne Terrance P. | -19,076 | $43.2928 | $825,853 |
| 2026-02-03 | Coyne Terrance P. | -6,195 | $42.8431 | $265,413 |
| 2026-02-03 | Coyne Terrance P. | -108,759 | $42.8432 | $4,659,584 |
| 2026-02-02 | Coyne Terrance P. | -5,843 | $42.0839 | $245,896 |
| 2026-02-02 | Coyne Terrance P. | -102,581 | $42.0839 | $4,317,009 |
| 2026-01-30 | Urist Marshall | -20,000 | $41.0905 | $821,810 |
| 2026-01-23 | Urist Marshall | -20,000 | $40.2555 | $805,110 |
| 2026-01-20 | Coyne Terrance P. | -3,750 | $39.3484 | $147,557 |
| 2026-01-20 | Coyne Terrance P. | -65,832 | $39.3484 | $2,590,384 |
| 2026-01-16 | Urist Marshall | -20,000 | $39.5173 | $790,346 |
| 2026-01-09 | Urist Marshall | -20,000 | $40.7817 | $815,634 |
| 2026-01-02 | Urist Marshall | -20,000 | $38.4825 | $769,650 |
| 2026-01-02 | Coyne Terrance P. | -3,750 | $38.4157 | $144,059 |
| 2026-01-02 | Coyne Terrance P. | -65,832 | $38.4157 | $2,528,982 |
| 2025-12-31 | Bassler Bonnie L | +967 | $38.7418 | $37,463 |
| 2025-12-26 | Urist Marshall | -20,000 | $39.319 | $786,380 |
| 2025-12-19 | Urist Marshall | -20,000 | $38.3791 | $767,582 |
| 2025-12-18 | Lloyd George W. | -30,654 | $38.4959 | $1,180,053 |
| 2025-12-17 | Lloyd George W. | -79,346 | $38.5688 | $3,060,280 |
| 2025-12-16 | Urist Marshall | -20,000 | $38.321 | $766,420 |
| 2025-12-15 | Coyne Terrance P. | -3,750 | $38.3601 | $143,850 |
| 2025-12-15 | Coyne Terrance P. | -65,832 | $38.3601 | $2,525,322 |
| 2025-12-05 | Urist Marshall | -18,242 | $39.1527 | $714,224 |
| 2025-12-05 | Urist Marshall | -23,334 | $39.1528 | $913,591 |
| 2025-12-03 | Lloyd George W. | -110,000 | $39.7728 | $4,375,008 |
| 2025-12-01 | Urist Marshall | -18,242 | $39.9 | $727,856 |
| 2025-12-01 | Urist Marshall | -23,333 | $39.9277 | $931,633 |
| 2025-12-01 | Coyne Terrance P. | -3,750 | $39.866 | $149,498 |
| 2025-12-01 | Coyne Terrance P. | -65,832 | $39.866 | $2,624,459 |
| 2025-11-24 | Coyne Terrance P. | -624 | $37.9595 | $23,687 |
| 2025-11-24 | Coyne Terrance P. | -3,126 | $38.6699 | $120,882 |
| 2025-11-24 | Coyne Terrance P. | -10,686 | $37.9604 | $405,645 |
| 2025-11-24 | Coyne Terrance P. | -55,146 | $38.6663 | $2,132,292 |
| 2025-11-19 | Lloyd George W. | -230 | $39.0331 | $8,978 |
| 2025-11-19 | Lloyd George W. | -2,770 | $38.2858 | $106,052 |
| 2025-11-19 | Lloyd George W. | -2,470 | $39.0067 | $96,347 |
| 2025-11-19 | Lloyd George W. | -25,530 | $38.2789 | $977,260 |
| 2025-11-19 | Lloyd George W. | -4,599 | $39.0071 | $179,394 |
| 2025-11-19 | Lloyd George W. | -47,401 | $38.2787 | $1,814,449 |
| 2025-11-19 | Lloyd George W. | -4,628 | $39.0077 | $180,528 |
| 2025-11-19 | Lloyd George W. | -47,798 | $38.2788 | $1,829,650 |
| 2025-11-17 | Coyne Terrance P. | -3,750 | $39.304 | $147,390 |
| 2025-11-17 | Coyne Terrance P. | -65,844 | $39.3041 | $2,587,939 |
| 2025-11-07 | Urist Marshall | -16,000 | - | - |
| 2025-11-07 | Urist Marshall | +160,000 | - | - |
| 2025-11-05 | Urist Marshall | +4,626 | - | - |
| 2025-11-05 | Lloyd George W. | +6,168 | - | - |
| 2025-11-05 | Coyne Terrance P. | +6,168 | - | - |
| 2025-11-05 | Hite Christopher | +6,168 | - | - |
| 2025-11-05 | Legorreta Pablo G. | +36,559 | - | - |